Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-15
2006-08-15
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000
Reexamination Certificate
active
07091190
ABSTRACT:
The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.
REFERENCES:
patent: 1109119 (1914-09-01), Ellis
patent: 3031376 (1962-04-01), Levin et al.
patent: 3584115 (1971-06-01), Gebhart et al.
patent: 3592930 (1971-07-01), Katz
patent: 3946035 (1976-03-01), Jacquet et al.
patent: 3987198 (1976-10-01), Young
patent: 4025645 (1977-05-01), Jelenko, III
patent: 4076799 (1978-02-01), Willer et al.
patent: 4186211 (1980-01-01), Debat
patent: 4199574 (1980-04-01), Schaeffer
patent: 4200655 (1980-04-01), Farah et al.
patent: 4258029 (1981-03-01), Moloney et al.
patent: 4360522 (1982-11-01), Schaeffer
patent: 4513008 (1985-04-01), Revici et al.
patent: 4624966 (1986-11-01), Yamamoto et al.
patent: 4670471 (1987-06-01), Clark
patent: 4684479 (1987-08-01), D'Arrigo
patent: 4865848 (1989-09-01), Cheng et al.
patent: 4874794 (1989-10-01), Katz
patent: 4879109 (1989-11-01), Hunter
patent: 4880634 (1989-11-01), Speiser
patent: 4897394 (1990-01-01), Zimmerman et al.
patent: 4900555 (1990-02-01), Cheng et al.
patent: 4940586 (1990-07-01), Cheng et al.
patent: 4950688 (1990-08-01), Bowser et al.
patent: 4956171 (1990-09-01), Chang
patent: 5030448 (1991-07-01), Hunter
patent: 5070107 (1991-12-01), Katz
patent: 5071879 (1991-12-01), Katz
patent: 5104656 (1992-04-01), Seth et al.
patent: 5154855 (1992-10-01), Sekiguchi et al.
patent: 5166219 (1992-11-01), Katz
patent: 5194451 (1993-03-01), Katz
patent: 5194654 (1993-03-01), Hosteler
patent: 5208257 (1993-05-01), Kabara
patent: 5216142 (1993-06-01), Horrobin et al.
patent: 5250236 (1993-10-01), Gasco et al.
patent: 5276020 (1994-01-01), Horrobin et al.
patent: 5380754 (1995-01-01), Miller et al.
patent: 5436234 (1995-07-01), Eibl
patent: 5484911 (1996-01-01), Hong et al.
patent: 5534554 (1996-07-01), Katz et al.
patent: 5567816 (1996-10-01), Schloemer et al.
patent: 5580571 (1996-12-01), Hostetler
patent: 5667492 (1997-09-01), Bologna et al.
patent: 5756737 (1998-05-01), Turchetta et al.
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 5952392 (1999-09-01), Katz et al.
patent: 6440980 (2002-08-01), Marcelletti et al.
patent: 0 526 666 (1991-08-01), None
patent: 0 875 233 (1998-11-01), None
patent: 0875233 (1998-11-01), None
patent: 2569108 (1990-09-01), None
patent: 198394 (1987-01-01), None
patent: WO8807866 (1988-10-01), None
patent: WO90/04388 (1990-05-01), None
patent: WO 94/16061 (1994-01-01), None
patent: WO 94/05258 (1994-03-01), None
patent: WO 9405258 (1994-03-01), None
patent: WO 95/16434 (1995-06-01), None
patent: WO 9516434 (1995-06-01), None
patent: WO 95/27479 (1995-10-01), None
patent: WO 9527479 (1995-10-01), None
patent: WO96/02244 (1996-02-01), None
patent: WO95/16434 (1996-06-01), None
patent: WO 96/40144 (1996-12-01), None
patent: WO 9640144 (1996-12-01), None
patent: WO 97/09978 (1997-03-01), None
patent: WO 9709979 (1997-03-01), None
patent: WO 97/13528 (1997-04-01), None
patent: WO 98/11887 (1998-03-01), None
patent: WO 98/18472 (1998-05-01), None
patent: WO 98/30244 (1998-07-01), None
patent: WO 9830244 (1998-07-01), None
Hungarian Search Report for Hungarian Application No. P0200294.
Antonian, et al. (1987), AL721,A Novel Membrane Fluidizer, Neuroscience and Biobehavioral Reviews, 11:399-413.
Bazan, Nicolas G., (1989)The Metabolism of Omega-3 Plyunsaturated Fatty Acids in the Eye: The Possible Role of Docosahexaenoic Acid and Decosanoids in Retinal Physiology and Ocular Pathology, Prog. Clin. biol. Res., 312: 95-112.
Blum et al., (1982),Overview of Acyclovir Pharmacokinetic Disposition in Adults and Children, Am. J. Med., 73:186-192.
Caruso et al., (1995),Expression of a Tat-Inducible Herpes Simplex Virus-Thymidine Kinase Gene Protects Acyclovir-Treated CD4 Cells from HIV-1 Spread by Conditional Suicide and Inhibition of Reverse Transcription, Virol, 206:495-503.
Cooper, et al. (1985)Effect of fatty acids and alcohols on the penetration of acyclovir across human skin in vitro, Jour. Pharm Science, 74:688-689.
Franken et al., (1996),Epstein-Barr virus-driven gene therapy for EBV-related lymphomas, Nature Medicine, 2:1379-1382.
Hirsch et al., (1996),Antiviral Agents, In Fields Virology Third Edition, 431-466.
Hostetler et al., (1997),Enhanced Oral Absorption and Antiviral Activity of 1-O-Octadecyl-sn-glycero-3-phospho-acyclovir and Related Compounds in Hepatitis B Virus Infection In Vitro, Biochem Pharmacol, 53:1815-1822.
Katz et al., (1991)Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex, Proc. Natl. Acad. Sci. USA, 88:10825-10829.
Katz et al., (1994)n-Docosanol: Broad Spectrum Anti-Viral Activity against Lipid-enveloped Viruses, Annals N.Y. Acad. Sciences, 724: 472-488.
McBride et al., (1987)Evaluation of Triacontanol-Containing Compounds as Anti-Inflammatory Agents Using Guinea Pig Models, Jour. Investigative Dermatology, 89:380-383.
O'Brien et al., (1990)Nucleoside Metabolism in Herpes Simplex Virus-Infected Cells following Treatment with Interferon and Acyclovir, a Possible Mechanism of Synergistic Antiviral Activity, Antimicrob Agents Chemother, 34:1178-1182.
Oliver et al., (1985),Inhibition of HSV-Transformed Murine Cells by Nucleoside Analogs, 2′NDG and 2′-nor-cGMP: Mechanisms of Inhibition and Reversal by Exogenous Nucleosides, Virol, 145, pp. 84-93.
Pope et al. (1996),Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug, J. Lipid Res., 37: pp. 2167-2178.
Pope et al., (1998),The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process, Antiviral Res., 40:85-94.
Sandra, et al. (1979)Liposome-Cell Interactions, J. Biol. Chem. 254:2244-2249.
Sands, et al. (1979)Extreme Sensitivity of Enveloped Viruses, including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols, Antimicrobial Agents and Chemotherapy, 15:67-73.
Snipes, et al. (1977)Inactivation of Lipid-Containing Viruses by Long-Chain, Alcohols, Antimicrob. Agents & Chemother., 11:98-104.
Tyring et al., (1998),A Randomized Placebo-Controlled Comparison of Oral Valacyclovir and Acyclovir in Immunocompetent Patients with Recurrent Genital Herpes Infections, Arch Dermatol, 134:185-191.
CAPLUS Abstract, AN 1996:304119, Nakayama et al. 1996.
International Search Report PCT/US97/16007—Jan. 21, 1998 (6 pages).
International Preliminary Examination Report PCT/US97/16007—Dec. 30, 1998 (7 pages).
European Search Report—EP 97941503—Nov. 25, 2002 (2 pages).
International Preliminary Examination Report—PCT/US00/05965—Aug. 7, 2001—(8 pages).
European Search Report filed in Equivalent European Application 05 07 5320, mailed Jun. 8, 2005.
Annals New York Academy of Sciences, 1994, vol. 723, pp. 472-488.
Proc. Natl. Acad. Sci. USA, 1991, vol. 88, pp. 10825-10829.
European Search Report for corresponding European Application No. 00912195.5 Oct. 4, 2005.
Official Communication in equivalent European Application No. 00 912 195.5—1216, mailed Feb. 10, 2006.
Katz David H.
Katz Lee R.
Khalil Mohammed H.
Marcelletti John F.
Pope Laura E.
Avanir Pharmaceuticals
Knobbe Martens Olson & Bear LLP
Lewis Patrick
LandOfFree
Synergistic inhibition of viral replication by long-chain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic inhibition of viral replication by long-chain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic inhibition of viral replication by long-chain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641573